Targeting cell cycle and hormone receptor pathways in cancer.

Authors

C E S Comstock, Thomas Jefferson University
M A Augello, Thomas Jefferson UniversityFollow
J F Goodwin, Thomas Jefferson UniversityFollow
R de Leeuw, Thomas Jefferson UniversityFollow
M J Schiewer, Thomas Jefferson UniversityFollow
W F Ostrander, Thomas Jefferson UniversityFollow
R A Burkhart, Thomas Jefferson UniversityFollow
A K McClendon, Thomas Jefferson UniversityFollow
Peter McCue, Thomas Jefferson UniversityFollow
Edouard J. Trabulsi, Thomas Jefferson UniversityFollow
Costas D. Lallas, Thomas Jefferson UniversityFollow
Leonard G Gomella, MD, Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA, 19107, USAFollow
M M Centenera, University of Adelaide, Adelaide, South Australia, Australia
Jonathan Brody, MD, Thomas Jefferson UniversityFollow
L M Butler, University of Adelaide, Adelaide, South Australia, Australia
W D Tilley, Thomas Jefferson University
K E Knudsen, PhD, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

11-28-2013

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Oncogene

Volume 32, Issue 48, November 2013, Pages: 5481-5491.

The published version is available at DOI: 10.1038/onc.2013.83. Copyright © Nature

Abstract

The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis is a critical modulator of cell cycle entry and is aberrant in many human cancers. New nodes of therapeutic intervention are needed that can delay or combat the onset of malignancies. The antitumor properties and mechanistic functions of PD-0332991 (PD; a potent and selective CDK4/6 inhibitor) were investigated using human prostate cancer (PCa) models and primary tumors. PD significantly impaired the capacity of PCa cells to proliferate by promoting a robust G1-arrest. Accordingly, key regulators of the G1-S cell cycle transition were modulated including G1 cyclins D, E and A. Subsequent investigation demonstrated the ability of PD to function in the presence of existing hormone-based regimens and to cooperate with ionizing radiation to further suppress cellular growth. Importantly, it was determined that PD is a critical mediator of PD action. The anti-proliferative impact of CDK4/6 inhibition was revealed through reduced proliferation and delayed growth using PCa cell xenografts. Finally, first-in-field effects of PD on proliferation were observed in primary human prostatectomy tumor tissue explants. This study shows that selective CDK4/6 inhibition, using PD either as a single-agent or in combination, hinders key proliferative pathways necessary for disease progression and that RB status is a critical prognostic determinant for therapeutic efficacy. Combined, these pre-clinical findings identify selective targeting of CDK4/6 as a bona fide therapeutic target in both early stage and advanced PCa and underscore the benefit of personalized medicine to enhance treatment response.

Recommended Citation

Comstock, C E S; Augello, M A; Goodwin, J F; de Leeuw, R; Schiewer, M J; Ostrander, W F; Burkhart, R A; McClendon, A K; McCue, Peter; Trabulsi, Edouard J.; Lallas, Costas D.; Gomella, MD, Leonard G; Centenera, M M; Brody, MD, Jonathan; Butler, L M; Tilley, W D; and Knudsen, PhD, K E, "Targeting cell cycle and hormone receptor pathways in cancer." (2013). Department of Cancer Biology Faculty Papers. Paper 60.
https://jdc.jefferson.edu/cbfp/60

PubMed ID

23708653